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Objective To investigate the antibiotic and biocide susceptibilities of clinical isolates of rarely encountered
Gram-negative, non-fermenting bacteria.
Methods Thirty Gram-negative non-fermenting bacterial strains were isolated from blood cultures of
oncology patients. These were studied for their resistance to 11 antibiotics. Their susceptibilities to seven
biocides used in hospitals were also examined.
Results Isolates of Stenotrophomonas maltophilia andOchrobactrum anthropiwere generally resistant to at least ﬁve
of the antibiotics, whereas isolates ofComamonas acidivorans, Flavobacterium oryzihabitans,Aeromonas hydrophila,
Sphingobacterium spiritivorum,Acinetobacter junii andAcinetobacter lwofﬁwere generally sensitive to at least nine of
the antibiotics. Trovaﬂoxacin and trimethoprim–sulfamethoxazole were the most effective antibacterial
agents tested, with 0% and 7%, respectively, of isolates being resistant, whereas 63% of isolates were resistant
to aztreonam. Some isolates, sensitive to meropenem and/or ceftazidime in vitro, possessed very high MBC/
MIC ratios for these b-lactams. Two out of three biocides used in hospital pharmacies showed lethal activity
towards all strains tested when used at less than one-third of their recommended in-use concentration.
Proceine 40 failed to give a 5 log reduction in bacterial cell number for the isolates tested when used at its
‘in-use’ concentration. A concentration of >500mg/L chlorhexidine was required to achieve a 5 log
reduction for the same isolates.
Conclusions We have examined the antibiotic susceptibilities of non-fermenting Gram-negative
bacterial strains isolated from immunocompromised patients. Despite being sensitive to certain antibiotics in
vitro, some isolates were still able to cause serious bacteremia. We have also reported for the ﬁrst time the
susceptibilities of non-fermenting Gram-negative bacteria to common biocides used in hospital infection
control, and have shown that some strains are able to persist at the ‘in-use’ concentration of particular
biocides. It is therefore important to study further this particular group of organisms, and, in particular, to
examine whether there exists a link between resistance to antibiotics and resistance to biocides.
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INTRODUCTION
The use of antibiotics, in particular b-lactams, has increased
dramatically in recent years, both therapeutically once infection
has occurred, and prophylactically, particularly for immuno-
compromised patients. Bacteria can resist the action of
antibiotics in many ways [1–3], including (1) the presence of an
enzyme that inactivates the antibiotic, (2) modiﬁcation of the
target of the antibiotic, thus reducing binding of the antibiotic
to the target, (3) reduced uptake of the antibiotic, and (4) active
efﬂux of the antibiotic. Resistance to an antibiotic, whatever the
mechanism, poses a major problem for therapeutic regimens
and treatment of infection.
The development and persistence of antibiotic resistance in
bacteria is an ongoing problem which has been the subject of a
great deal of research. By contrast, biocide (collectively disin-
fectant, antiseptic and preservative) resistance is an emerging
problem which is only now attracting greater interest [4,5].
Resistance to these agents displayed by Gram-negative bacteria
is often intrinsic, whereby cellular impermeability or an efﬂux
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system(s) prevents sufﬁciently high concentrations of the bio-
cide reaching target sites within the cell [4]. Resistance may also
be mediated by mutation or acquisition of genetic elements
such as plasmids, integrons or transposons [6].
Non-fermenting Gram-negative bacteria (NFGNB), such as
Stenotrophomonas maltophilia, Acinetobacter spp., Alcaligenes spp.,
Aeromonas spp., Chryseobacterium spp., Ochrobactrum anthropi,
Comamonas acidivorans, and Sphingobacterium spiritivorum, have
been regarded historically as either environmental contaminants
or organisms of low pathogenicity, and hence not clinically
signiﬁcant. However, their emergence as signiﬁcant causes of
nosocomial bacteremia has more recently been noted, parti-
cularly with regard to immunocompromised patients [7–13].
Many reports describe the antimicrobial susceptibilities of
NFGNB to various antibiotics [8,9,14–21], whereas very little
is known about the susceptibility of these organisms to biocides.
We therefore decided to study the susceptibility proﬁles of
clinical isolates of NFGNB for both clinically relevant anti-
biotics used in therapy and compounds used as biocides.
MATERIALS AND METHODS
Clinical isolates of NFGNB
Thirty isolates of NFGNB have been isolated from blood
cultures of oncology patients over the past 10 years. The
NFGNB isolates were identiﬁed using a commercial biochem-
ical proﬁle kit (Api20NE; bioMe´rieux, Marcy L’Etoile, France)
according to the manufacturer’s instructions, supported by 16S
rRNA DNA sequencing. Primers used for ampliﬁcation were
‘rDNA’ forward (50-TCAGATTTGAACGCTGGCGGCA-
30) and reverse (50-CGTATTACCGCGGCTGCTGCCAC-
30). These primers bind to highly conserved sequences in the
16S rRNA gene and amplify a 500-bp fragment of the gene
where the majority of sequence variation is known to occur in
different Gram-negative bacteria. Subsequent sequences were
analyzed using the Ribosomal Database Project (Michigan State
University, USA).
Determination of theminimum inhibitory concentration
(MIC) of an antibiotic
The MIC was determined on Mueller–Hinton agar (Oxoid,
Basingstoke, UK) using E test strips according to the manu-
facturer’s instructions (AB Biodisk, Solna, Sweden).
Determination of theminimal bactericidal concentration
(MBC) of an antibiotic
TheMBCwas determined by the macrobroth dilution method.
Cultures grown to mid-log phase were diluted 1 : 100 in fresh
IsoSensitest broth containing antibiotic at 1, 2, 4 and 8
the MIC (as determined in IsoSensitest broth). These cultures
were incubated overnight at 37 8C with shaking. On the
following day, 100 mLwas taken from the cultures where growth
was not observed and plated on antibiotic-free IsoSensitest agar.
These plates were incubated overnight at 37 8C. The number of
colonies on the agar plates was counted, and the MBC was
noted as the lowest concentration of antibiotic capable of killing
99.9% of the cells in the innoculum.
Determination of MICs of biocides
The MICs of chlorhexidine diacetate (Sigma, Poole, UK),
benzalkonium chloride (ICN Biochemicals, Cleveland, Ohio,
USA), phenol, Klericide A containing a bisbiguanide and a
quaternary ammonium compound (Shield Medicare Ltd,
Farnham, UK), Klericide B containing ClO2 and a quaternary
ammonium compound (Shield Medicare), Proceine 40 (Agma
Plc, Haltworth, UK), broadly equivalent to a quaternary
ammonium compound, and Texpure (Texwipe Co., Upper
Saddle River, New Jersey, USA), a detergent, were determined
using the agar incorporation method. MICs were also deter-
mined for all of the biocides, except phenol and Texpure, with
ethylenediamine tetra-acetic acid (EDTA) (Sigma) added to the
agar at concentrations of 1, 0.5 and 0.1mM. An overnight
culture incubated at 30 8C in nutrient broth (Oxoid) was
diluted 1 : 10 in sterile water and used as the innoculum. A
Denley multipoint inoculator was used to spot 1mL of the
bacterial suspension on nutrient agar (Oxoid) containing dilu-
tions of the appropriate biocide. Nutrient agar lacking biocide
was used as a control. Plates were incubated at 30 8C and growth
was checked at 24 and 48 h. The MIC was deﬁned as the lowest
concentration of biocide which inhibited the growth of single
colonies.
Bactericidal activity of biocides
A quantitative Suspension Test [22] was used to assess the log
reduction of bacterial cell numbers. When Klericide A and B
were assessed, concentrations in sterile water of 0.5%, 1.0%,
5.0% and 10% of the ‘in-use’ concentration were used. Cells
from 10mL of a culture grown overnight were harvested at
4000 g for 10min. The cell pellet was resuspended in 5mL of
sterile water to produce a suspension of approximately
5 108CFU/mL. One milliliter of the suspension was then
mixed with 9mL of the biocide solution and left for 5min. One
hundred microliters of the suspension was removed, and the
biocide was neutralized in 900 mL of appropriate neutralizer.
For Klericide A this was a 5% Tween (Sigma), 0.75% azolectin
(Sigma) mixture, and for Klericide B, 0.5% sodium thiosulfate
(Fisher Scientiﬁc, Loughborough, UK). The neutralized cell
suspension was then serially diluted ﬁve more times in neu-
tralizer. From each dilution, 10-mL samples were dropped in
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triplicate on nutrient agar and allowed to dry before incubation
at 30 8C for 24 h. After incubation, an appropriate dilution was
chosen for counting. The test was repeated to simulate ‘dirty’
conditions by mixing the test suspension with a 3% (w/v)
bovine serum albumin (BSA; Sigma) solution for 2min before
inoculating 2mL of the mixture into 8mL of the biocide
solution. BSA is used to mimic organic soiling, and hence
the ‘dirty’ test simulates practical ‘in-use’ conditions [22].
Suspension tests were also carried out for Proceine 40 and
chlorhexidine diacetate, the neutralizer used for these being
the same as that for Klericide A. A further test with Proceine 40
was carried out, where samples were also removed and neu-
tralized at 60-s intervals after mixing of the cell suspension
and biocide. In all cases, the tests were carried out in quad-
ruplicate. The microbicidal effect (ME) was determined by
subtracting the log number of survivors from the log number of
cells at time 0.
RESULTS
MICs andMBCs of antibiotics
The results of MIC testing of 11 antibiotics against the 30
NFGNB isolates are shown in Table 1. Each value has been
designated resistant, intermediate, or sensitive (Table 1), accord-
ing to the NCCLS breakpoints for the non-Enterobacteriaceae
[23].
Different non-fermentative species differed in their suscept-
ibilities to the antibiotics tested. Isolates of Stenotrophomonas
maltophilia andO. anthropiwere generally resistant to at least ﬁve
of the antibiotics, whereas isolates of Comamonas acidivorans,
Flavobacterium oryzihabitans, Aeromonas hydrophila, Sphingobacter-
ium spiritivorum, Acinetobacter junii and Acinetobacter lwofﬁ were
generally sensitive to at least nine of the antibiotics. The overall
percentage of resistant isolates for each of the antibiotics is as
follows: aztreonam 63%, cefotaxime 60%, piperacillin–tazobac-
tam 37%, meropenem 27%, gentamicin 26%, ceftazidime 23%,
cefepime 23%, tetracycline 16%, chloramphenicol 10%,
trimethoprim–sulfamethoxazole 7%, and trovaﬂoxacin 0%.
A number of isolates with low MICs for meropenem and
ceftazidime were chosen at random for further analysis. Given
that the patients from whom these isolates were obtained had
received multiple antibiotic therapies, including b-lactams, it
was decided to determine the MBCs of meropenem and
ceftazidime for some of these strains. TheMBCs of meropenem
and ceftazidime were determined for isolates N528 (Comamonas
acidivorans), J611a (Chryseomonas luteola), and O91 (Acinetobacter
junii), and of meropenem for isolate N217 I (O. anthropi) using a
broth dilution method. In all cases, the MBC/MIC ratio was
>8, meaning that the concentrations of these antibiotics
required to kill the organisms are more than eight-fold greater
than those required to inhibit growth.
MICs of biocides
MICs of a subset of 14 isolates of NFGNB were determined
for chlorhexidine diacetate and benzalkonium chloride in the
presence and absence of EDTA (Figure 1). Of the strains with
MICs >100mg chlorhexidine diacetate/L, Aeromonas hydro-
phila P881 had an MIC of 250mg/L and four had MICs of
175mg/L (Table 2). Alcaligenes sp. J370 and Sphingobacterium
spiritivorum P780 I were the most sensitive strains (MICs of
10mg/L) to chlorhexidine diacetate. None of the strains tested
had an MIC of >100mg/L for benzalkonium chloride, and
strain P780 I was again the most sensitive to this antibacterial
(MIC 10mg/L). In all cases, the inclusion of EDTA (0.5mM)
reduced the MICs of chlorhexidine diacetate and benzal-
konium chloride (Figure 1), and this effect was enhanced
(data not shown) at higher EDTA concentrations. The MICs
for phenol were spread over a large range from 125 to
1500 mg/L.
The results for the commercial biocide preparations tested are
expressed as the percentage of their ‘in-use’ concentration
(Table 2). The Klericides come pre-diluted and ready for use.
However, Proceine 40 and Texpure require dilution, and are
used at 0.6% (v/v) and 3% (v/v) dilutions of the concentrate
provided, respectively. Klericide A had MICs between 2% and
9%, with MICs greater than 5% against the majority of the
strains tested. Klericide B produced considerably lower MICs,
with anMIC of 4% or less against 11 of the 14 strains tested. The
highest MIC of Klericide B was 6% for strains Acinetobacter
baumannii F301 I and Alcaligenes sp. J370. Strain P780 I was most
sensitive to Klericide A and B (MICs 2% and 0.5%, respec-
tively). Proceine 40 and Texpure showed higher MICs; Pro-
ceine 40 had MICs >4% against all but two of the strains, and
Figure1 MICs of chlorhexidine diacetate (CHX) and benzalkonium chloride
(BZK), with andwithout the additionof EDTA at 0.5mM, for14 non-ferment-
ing Gram-negative bacilli isolates.
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Table1 MICs (mg/L) of10 antibiotics against 30 non-fermenting Gram-negative bacilli isolates, as determined by E test
CTZ CEF CTX MER AZT PIP/TAZ GENT TROV TRI/SUL TET CHL
Alcaligenes spp.
F136 12 (I) 2 (S) 16 (I) 0.38 (S) 48 (R) 3 (S) 24 (R) 0.094 (S) 6 (R) 2 (S) 24 (I)
J370 3 (S) 4 (S) >16 (R) 0.125 (S) >256 (R) 0.5 (S) 2 (S) 1.5 (S) 0.016 (S) 0.75 (S) 6 (S)
Comamonas acidivorans
N528 0.5 (S) 6 (S) 2 (S) 0.094 (S) 3 (S) 1.5 (S) >256 (R) 0.25 (S) 0.094 (S) 3 (S) 12 (I)
Chryseomonas luteola
J611a 1.5 (S) 1 (S) 1 (S) 0.38 (S) 8 (S) 8 (R) 16 (R) 0.38 (S) 0.094 (S) 8 (S) 3 (S)
P559 II 8 (S) 1.5 (S) >16 (R) >32 (R) >256 (R) 2 (S) 4 (S) 0.012 (S) 0.094 (S) 8 (S) 6 (S)
Chryseobacterium indologenes
P567A 8 (S) 1.5 (S) >16 (R) >32 (R) >256 (R) 3 (S) 6 (S) 0.012 (S) 0.094 (S) 8 (S) 8 (S)
N217 II 2 (S) 0.38 (S) >16 (R) >32 (R) >256 (R) 2 (S) 8 (S) 0.016 (S) 0.125 (S) 16 (R) 16 (I)
P198A 2 (S) 0.38 (S) >16 (R) >32 (R) >256 (R) 2 (S) 8 (S) 0.016 (S) 0.125 (S) 16 (R) 16 (I)
Chryseobacteriummeningosepticum
O70 2 (S) 0.5 (S) >16 (R) 8 (I) >256 (R) 2 (S) 8 (S) 0.023 (S) 0.19 (S) 12 (I) 16 (I)
Ochrobactrum anthropi
N217 I >256 (R) 64 (R) >16 (R) 0.25 (S) >256 (R) >256 (R) 1.5 (S) 0.5 (S) 0.094 (S) 0.25 (S) 16 (I)
N531II >256 (R) 64 (R) >16 (R) 0.25 (S) >256 (R) >256 (R) 1.5 (S) 0.5 (S) 0.094 (S) 0.25 (S) 16 (I)
P566 II >256 (R) 64 (R) >16 (R) 0.25 (S) >256 (R) >256 (R) 1.5 (S) 0.5 (S) 0.094 (S) 0.25 (S) 16 (I)
Sphingobacterium spiritivorum
N546 I 1.5 (S) 1.5 (S) 0.75 (S) 0.064 (S) >256 (R) 1.5 (S) 128 (R) 0.006 (S) 0.19 (S) 0.25 (S) 1.5 (S)
O749 1.5 (S) 1.5 (S) 0.75 (S) 0.064 (S) >256 (R) 1.5 (S) 128 (R) 0.006 (S) 0.19 (S) 0.25 (S) 1.5 (S)
P780 I 1.5 (S) 1.5 (S) 0.75 (S) 0.064 (S) >256 (R) 1.5 (S) 128 (R) 0.006 (S) 0.19 (S) 0.25 (S) 1.5 (S)
Flavimonas oryzihabitans
8854 0.5 (S) 0.19 (S) 2 (S) 0.004 (S) 12 (I) 1.5 (S) 0.047 (S) 0.047 (S) 0.38 (S) 0.75 (S) 4 (S)
Aeromonas hydrophila
P881 0.19 (S) 0.047 (S) <0.25 (S) 0.023 (S) 0.016 (S) 1.5 (S) 0.5 (S) 0.032 (S) 0.38 (S) 0.5 (S) 0.75 (S)
P211I 0.25 (S) 0.064 (S) <0.25 (S) 0.023 (S) 0.016 (S) 0.75 (S) 0.38 (S) 0.047 (S) 0.5 (S) 0.5 (S) 0.75 (S)
J610 >256 (R) >256 (R) >16 (R) 0.094 (S) >256 (R) 1 (S) 0.064 (S) 0.016 (S) 0.003 (S) 0.25 (S) 4 (S)
P478A 0.25 (S) 0.047 (S) <0.25 (S) 0.016 (S) 0.016 (S) 0.075 (S) 0.038 (S) 0.047 (S) 0.5 (S) 0.5 (S) 0.75 (S)
Acinetobacter baumannii
K277 4 (S) 4 (S) >16 (R) 0.5 (S) 24 (I) 8 (R) 0.25 (S) 0.023 (S) 0.19 (S) 3 (S) 128 (R)
F301I 12 (I) 2 (S) >16 (R) 0.38 (S) 48 (R) 2 (S) 24 (R) 0.064 (S) 8 (R) 2 (S) 12 (I)
J686 II 6 (S) 4 (S) >16 (R) 0.5 (S) 24 (I) 8 (R) 0.25 (S) 0.032 (S) 0.19 (S) 3 (S) 128 (R)
P558 Ib 4 (S) 3 (S) >16 (R) 0.38 (S) 12 (I) 4 (R) 0.25 (S) 0.047 (S) 0.38 (S) 2 (S) 24 (I)
Acinetobacter junii
O91 3 (S) 0.5 (S) 3 (S) 0.094 (S) 12 (I) <0.016 (S) 0.094 (S) 0.012 (S) 0.008 (S) 0.75 (S) 1.5 (S)
Acinetobacter lwoffi
O948 3 (S) 0.5 (S) 3 (S) 0.094 (S) 12 (I) <0.016 (S) 0.125 (S) 0.012 (S) 0.008 (S) 0.75 (S) 1 (S)
Stenotrophomonas maltophilia
G478 96 (R) 32 (R) >16 (R) >32 (R) >256 (R) 48 (R) 4 (S) 1 (S) 0.125 (S) 48 (R) 6 (S)
N531 1.5 (S) 8 (S) >16 (R) >32 (R) >256 (R) 24 (R) 12 (I) 0.094 (S) 0.094 (S) 6 (S) 3 (S)
K279a 96 (R) 32 (R) >16 (R) >32 (R) >256 (R) 192 (R) 4 (S) 1.5 (S) 0.125 (S) 64 (R) 8 (S)
J675 I 256 (R) >256 (R) >16 (R) >32 (R) >256 (R) >256 (R) 24 (R) 0.19 (S) 0.064 (S) 12 (I) 12 (I)
CTZ, ceftazidime; CEF, cefepime; CTX, cefotaxime; MER, meropenem; AZT, aztreonam; PIP/TAZ, piperacillin^tazobactam; GENT, gentamicin; TROV, trovafloxacin; TRI/SUL, trimethoprim^sulfamethoxazole; TET,











































Texpure had MICs of 33.3% or more against 13 of the 14 strains
tested.
The addition of 0.5mM EDTA reduced the MICs of
Proceine 40 and Klericides A and B to 2% or less, with the
exception of Aeromonas hydrophila P881, against which Proc-
eine 40 had an MIC of 5% with each concentration of
EDTA used.
Microbicidal effects of biocides
At low concentrations (0.5% and 1.0% of the ‘in-use’ concen-
tration) in the absence of organic material, Klericides A and B
had comparable activities against the four strains tested, as
demonstrated by the log reduction of bacterial cell number
(Tables 3 and 4). The performance of both biocides, at most
concentrations, was impaired in the presence of 3% BSA.
Higher concentrations of Klericide B were more effective than
Klericide A, especially under ‘clean’ conditions. Under our
laboratory test conditions, Proceine 40 failed to give a 5 log
reduction in bacterial cell numbers after a 5-min exposure for
isolates Acinetobacter baumannii F301 I (log reduction of
3.935 0.872) and Stenotrophomonas maltophilia G478 (log
reduction of 4.225 0.143) when it was used at its suggested
‘in-use’ concentration (0.6%) for ﬂoor cleaning. Further tests
with Acinetobacter baumannii F301 I over a 5-min period, with
samples taken at 60-s intervals, showed the reduction in viable
cell number to be almost linear over the 5-min period following
exposure to Proceine 40 (data not shown). Strains of Acineto-
bacter baumannii (F301 I) and Stenotrophomonas maltophilia (G478)
required a concentration of >500mg/L chlorhexidine diace-
tate to give a 5 log reduction in bacterial cell number following a
5-min exposure.
DISCUSSION
The NFGNB isolates in this study were obtained from blood
cultures of oncology and bone marrow transplant patients. The
patients from whom the strains were isolated were generally
immunocompromised due to chemotherapy, and had intrave-
nous central lines. Many patients had recurrent bacteremia,
despite receiving multiple antibiotic therapies, which included
meropenem, ceftazidime and piperacillin–tazobactam. Owing
to the increasing isolation of NFGNB from immunocompro-
mised patients [7–13], it is important to determine the anti-
biotics to which these organisms are truly susceptible. Results of
the determination of the MICs of a number of antibiotics
against the 30 NFGNB isolates showed different susceptibilities
in different species, generally in line with those in previous
reports [8,9,14–21]. Our results indicate that several of the
isolates were sensitive to certain antibiotics in vitro, despite their
abilities to still cause bacteremia after antibiotic therapy. To
examine this ﬁnding further, the MBC values of four isolates,
each of which has a low MIC for meropenem and/or cefta-
zidime, were determined. All of these isolates were found to
have high MBC/MIC ratios for these b-lactams. If the con-
centration of antibiotic given to the patient is below the MBC,
then the antibiotic will only temporarily inhibit the growth of
any susceptible microorganisms. When the antibiotic is with-
drawn, the possibility exists that the organisms may re-prolif-
erate, potentially causing prolonged infection. Organisms that,
in vitro, appear to be sensitive to those b-lactams used clinically
may thus cause serious bacteremias. This phenomenon has been
observed in other cases of O. anthropi bacteremia [24].
In addition to studying the antibiotic susceptibilities of these
NFGNB strains, their susceptibilities to biocides were also
Table2 MICs of seven biocides against14 non-fermenting Gram-negative bacilli isolates











Alcaligenes spp. F136 6 4 5 33.3 175 25 1250
Alcaligenes spp. J370 5 6 4 33.3 10 75 250
Comamonas acidivorans N528 5 2 9 33.3 50 100 1250
Chryseomonas luteola J611a 9 3 6 50 80 100 1250
Chryseobacterium indologenes P567a 4 3 4 50 175 100 1000
Ochrobactrum anthropi N217I 6 1 4 50 30 10 750
Sphingobacterium spiritivorum P780 I 2 0.5 1 50 10 10 1500
Aeromonas hydrophilia P881 3 2 4 50 250 100 1250
Acinetobacter baumannii K277 6 3^4 4 33.3 125 50 1250
Acinetobacter baumannii F301I 8 6 5 10 175 100 1000
Stenotrophomonas maltophilia G478 8 5 6 33.3 175 100 1000
Stenotrophomonas maltophilia J675 I 8 3 6 50 30 100 1000
Chryseobacteriummeningosepticum O70 3 1 3 33.3 80 75 1000
Flavimonas oryzihabitans 8854 9 4 6 33.3 30 75 1250
MICs for Klericide A (Kl A), Klericide B (Kl B), Proceine 40 andTexpure are expressed as a percentage of their ‘in-use’concentration. MICs for chlorhexidine
(CHX), benzalkonium chloride (BZK) and phenol are expressed as mg/L.
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Table3 Microbicidal effect of KlericideA (Kl A), shown as log reduction in bacterial cell number after 5-min exposure, in ‘clean’ (0% BSA) and ‘dirty’ (3% BSA) conditions; mean standard deviation
0.5% Kl A 1.0% Kl A 5.0% Kl A 10.0% Kl A
0% BSA 3% BSA 0% BSA 3%BSA 0%BSA 3%BSA 0%BSA 3% BSA
Chryseobacterium indologenes P567A 2.3100.229 2.5530.079 2.6380.116 2.7030.420 >6.00 4.5030.170 NM 4.6780.441
Stenotrophomonas maltophiliaG478 2.8880.527 1.0600.133 3.4450.246 1.7830.835 5.9130.118 3.5780.098 NM >6.00
Stenotrophomonas maltophiliaJ675 I 0.3300.253 0.4800.197 1.3400.489 0.9900.093 3.3630.109 2.3850.270 >6.00 5.3130.581
Acinetobacter baumannii F301I 3.3050.482 1.4430.334 3.9780.031 2.0330.129 >6.00 5.9230.092 NM NM
Concentrations of KlericideA refer to percentages of ‘in-use’concentration. NM, not measured.
Table4 Microbicidal effect of Klericide B (Kl B), shown as log reduction in bacterial cell number after 5-min exposure, in ‘clean’ (0% BSA) and ‘dirty’ (3% BSA) conditions; mean standard deviation
0.5% Kl B 1.0% Kl B 5.0% Kl B 10.0% Kl B
0%BSA 3%BSA 0%BSA 3% BSA 0% BSA 3% BSA 0%BSA 3%BSA
Chryseobacterium indologenes P567A 2.4430.095 1.8250.321 3.3700.318 2.2700.644 >6.00 5.2930.165 NM NM
Stenotrophomonas maltophiliaG478 1.2700.074 0.6600.105 2.7200.764 1.0800.255 >6.00 4.6851.562 NM >6.00
Stenotrophomonas maltophiliaJ675 I 1.2800.159 0.5280.199 3.2000.181 1.0930.162 >6.00 4.1150.535 NM >6.00
Acinetobacter baumannii F301I 2.0500.078 1.7100.557 3.1300.168 2.8820.099 >6.00 >6.00 NM NM











































determined. There are two views on how biocide resistance
should be deﬁned: (1) increase in minimum inhibitory con-
centration (MIC) or an MIC higher than that of a reference
strain; and (2) a point at which bacteria are non-susceptible to
the ‘in-use’ concentration of the biocide. MICs for the bis-
biguanide chlorhexidine diacetate for some strains are higher
than those (10–50mg/L) reported to be inhibitory to Gram-
negative bacteria [5], with nine of the 14 strains having MICs
of 50mg/L or more. These relatively high levels of chlor-
hexidine diacetate non-susceptibility can be attributed to the
failure of the biocide to reach its target sites within the cell
[25]. This value is still signiﬁcantly lower than the MIC of
800mg/L found for Proteus mirabilis and Pseudomonas aeruginosa
isolated from catheters washed out with chlorhexidine diacetate
[26]. MICs for a quaternary ammonium compound (bezalk-
onium chloride) for all isolates were less than 100mg/L.
Pseudomonad species were termed resistant if they were able
to grow in broth containing 200mg benzalkonium chloride/L
[27]. MICs of phenol varied considerably (125–1500mg/L) but
were below the concentration normally used (5000mg/L) as a
preservative.
Klericide B is stated as being the more effective of the two
Klericide products, because of its stabilized ClO2 component.
Our MIC data support this view; 11 of 14 strains were inhibited
by a concentration of 4% or less for Klericide B, whereas most of
the strains tested had MICs of >5% for Klericide A. MICs for
the ﬂoor cleaners Proceine 40 and Texpure were higher than
those obtained for Klericides A and B, the latter agents usually
being used on more critical work surfaces such as aseptic
preparation isolators or laminar airﬂow cabinets. Texpure is a
detergent-based cleaner, and the MICs obtained of 33.3%
show that it is a less efﬁcacious antimicrobial product than the
others tested. However, under certain conditions of use, sur-
face-active properties may contribute to the in situ effectiveness
of a biocide, by physically removing bacteria from a surface. In
all cases, MICs were reduced signiﬁcantly by the addition of
EDTA, which potentiates entry of the biocide into the target
cell by increasing the permeability of the outer membrane [4].
This is most markedly demonstrated by the reduction of the
Proceine 40 and chlorhexidine diacetate MICs.
Bactericidal testing was undertaken by a method based on the
European Suspension Test (EST). Although the EST has been
shown to be subject to variability [28], it remains a useful test to
discriminate between highly effective (ME> 5 log reduction in
bacterial cell number after 5min) and ineffective biocides [29].
Klericide A and B produced >5 log reduction in 5min when
tested at 10.0% of their in-use concentrations in clean condi-
tions, and only when 3% BSAwas added did Klericide A fail to
do so against two of the strains tested (Chryseobacterium indolo-
genes P567A and Stenotrophomonas maltophilia J675 I). Conver-
sely, Proceine 40 consistently failed to give a 5 log reduction in
bacterial cell number for isolates F301 I (Acinetobacter baumannii)
and G478 (Stenotrophomonas maltophilia) when it was tested at its
recommended ‘in-use’ concentration for ﬂoor disinfection.
However, like Texpure, Proceine 40 has surface-active char-
acteristics that may contribute to its in situ activity. For isolates
F301 I and G478, the concentration of chlorhexidine diacetate
required to achieve a 5 log reduction in bacterial cell number
was >500mg/L.
There have been a number of investigations into possible
links between biocide and antibiotic resistance [26,30–33].
With emerging pathogens showing resistance to many anti-
biotics, it is of interest to examine whether they also show
reduced susceptibility to biocides. If this were found to be the
case, then investigating the extent to which the two factors are
linked is of prime clinical signiﬁcance, given the possibility of
biocides selecting antibiotic-resistant organisms. Further inves-
tigations with a larger number of these NFGNB strains may
provide greater insight into a possible link.
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